Suppr超能文献

长期的肺鼠疫保护与外周器官(而非肺部)的细胞免疫相关。

Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

机构信息

Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, 903 S., 4th Street, Hamilton, MT 59840, USA.

出版信息

Vaccine. 2010 Sep 14;28(40):6562-72. doi: 10.1016/j.vaccine.2010.07.072. Epub 2010 Aug 3.

Abstract

Protection against the intracellular bacterium Francisella tularensis within weeks of vaccination is thought to involve both cellular and humoral immune responses. However, the relative roles for cellular and humoral immunity in long lived protection against virulent F. tularensis are not well established. Here, we dissected the correlates of immunity to pulmonary infection with virulent F. tularensis strain SchuS4 in mice challenged 30 and 90 days after subcutaneous vaccination with LVS. Regardless of the time of challenge, LVS vaccination protected approximately 90% of SchuS4 infected animals. Surprisingly, control of bacterial replication in the lung during the first 7 days of infection was not required for survival of SchuS4 infection in vaccinated mice. Control and survival of virulent F. tularensis strain SchuS4 infection within 30 days of vaccination was associated with high titers of SchuS4 agglutinating antibodies, and IFN-γ production by multiple cell types in both the lung and spleen. In contrast, survival of SchuS4 infection 90 days after vaccination was correlated only with IFN-γ producing splenocytes and activated T cells in the spleen. Together these data demonstrate that functional agglutinating antibodies and strong mucosal immunity are correlated with early control of pulmonary infections with virulent F. tularensis. However, early mucosal immunity may not be required to survive F. tularensis infection. Instead, survival of SchuS4 infection at extended time points after immunization was only associated with production of IFN-γ and activation of T cells in peripheral organs.

摘要

在接种疫苗后的数周内,针对细胞内细菌弗朗西斯菌的保护作用被认为涉及细胞免疫和体液免疫反应。然而,细胞免疫和体液免疫在针对强毒弗朗西斯菌的长期保护中的相对作用尚未得到很好的确定。在这里,我们在接种 LVS 后 30 天和 90 天挑战皮下接种强毒 F. tularensis SchuS4 菌株的小鼠中,剖析了对肺部感染的免疫相关性。无论挑战时间如何,LVS 疫苗接种都能保护约 90%的 SchuS4 感染动物。令人惊讶的是,在接种疫苗的小鼠中,控制感染后的第 7 天肺部细菌复制并不需要存活 SchuS4 感染。在接种疫苗后 30 天内控制和存活强毒 F. tularensis SchuS4 感染与高滴度的 SchuS4 凝集抗体以及肺部和脾脏中多种细胞类型产生的 IFN-γ有关。相比之下,在接种疫苗后 90 天感染 SchuS4 的存活仅与脾 IFN-γ产生细胞和激活的脾 T 细胞有关。这些数据共同表明,功能性凝集抗体和强大的粘膜免疫与早期控制强毒弗朗西斯菌的肺部感染有关。然而,早期的粘膜免疫可能不是存活弗朗西斯菌感染所必需的。相反,在免疫接种后延长时间点感染 SchuS4 的存活仅与外周器官中 IFN-γ的产生和 T 细胞的激活有关。

相似文献

1
Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.
Vaccine. 2010 Sep 14;28(40):6562-72. doi: 10.1016/j.vaccine.2010.07.072. Epub 2010 Aug 3.
2
Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.
Vaccine. 2017 Dec 15;35(50):7001-7009. doi: 10.1016/j.vaccine.2017.10.053. Epub 2017 Nov 6.
4
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.
8
Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.

引用本文的文献

1
Highly tail-asymmetric lipids interdigitate and cause bidirectional ordering.
J Lipid Res. 2025 May;66(5):100797. doi: 10.1016/j.jlr.2025.100797. Epub 2025 Apr 4.
2
Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent .
J Immunol. 2022 Mar 1;208(5):1180-1188. doi: 10.4049/jimmunol.2100915. Epub 2022 Feb 11.
4
Cutting Edge: Lung-Resident T Cells Elicited by SARS-CoV-2 Do Not Mediate Protection against Secondary Infection.
J Immunol. 2021 Nov 15;207(10):2399-2404. doi: 10.4049/jimmunol.2100608. Epub 2021 Oct 4.
5
Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity.
iScience. 2021 Aug 24;24(9):103025. doi: 10.1016/j.isci.2021.103025. eCollection 2021 Sep 24.
7
Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.
Clin Transl Immunology. 2021 Jan 19;10(1):e1239. doi: 10.1002/cti2.1239. eCollection 2021.
8
Validation and Application of a Bench Top Cell Sorter in a BSL-3 Containment Setting.
bioRxiv. 2020 Jul 31:2020.07.30.229146. doi: 10.1101/2020.07.30.229146.
9
Evaluation of an outbred mouse model for Francisella tularensis vaccine development and testing.
PLoS One. 2018 Dec 11;13(12):e0207587. doi: 10.1371/journal.pone.0207587. eCollection 2018.
10
Differential Cultivation of Influences Live Vaccine Protective Efficacy by Altering the Immune Response.
Front Immunol. 2018 Jul 10;9:1594. doi: 10.3389/fimmu.2018.01594. eCollection 2018.

本文引用的文献

2
Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma.
Microbes Infect. 2010 Jan;12(1):28-36. doi: 10.1016/j.micinf.2009.09.012. Epub 2009 Sep 23.
4
Identification of an essential Francisella tularensis subsp. tularensis virulence factor.
Infect Immun. 2009 Jan;77(1):152-61. doi: 10.1128/IAI.01113-08. Epub 2008 Nov 3.
5
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4.
Infect Immun. 2009 Jan;77(1):180-95. doi: 10.1128/IAI.00879-08. Epub 2008 Nov 3.
6
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.
Immunol Rev. 2008 Oct;225:244-55. doi: 10.1111/j.1600-065X.2008.00689.x.
7
Tularemia.
Infect Dis Clin North Am. 2008 Sep;22(3):489-504, ix. doi: 10.1016/j.idc.2008.03.004.
8
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验